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Introduction 1
Familial hypercholesterolaemia (FH) is characterised by elevated low-density lipoprotein 2 cholesterol (LDL-C) from birth, and is associated with elevated risk of coronary heart disease 3 (CHD). 1 A recent general population study described an odds of CHD for the average and no model for adult screening has been described. There are also theoretical reasons to 2 favour screening in childhood. The false positive and false negative FH case detection rates 3 for given cholesterol thresholds appear to be most favourable at young ages, 23 and screening 4 at younger ages enables intervention at an early stage of atherosclerosis development, when 5 maximum benefit can still be obtained via lifestyle adaptations and LMT. The feasibility of 6 US at age 1-2 years has recently been demonstrated, 24 but cost-effectiveness is unclear.
8
We therefore aimed to determine whether US for FH at 1-2 years could be a cost-effective 9 adjunct to CT in the UK. 
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25
As relevant data were sparse, no formal syntheses were undertaken and model parameters 26 were estimated conservatively.
28
Model structure and inputs
29
The decision tree used to model US ( Figure 1a) 
31
CHD death, risks, respectively). 38 The CTT values were assumed applicable to both primary 32 and secondary events.
34
Cycle health state outcomes were weighted with the utilities described in CG181, 32 and costs
35
and effects were discounted, enabling calculation of discounted quality-adjusted life year M A N U S C R I P T A C C E P T E D 
21
Management of uncertainty and calculations
22
To include parameter uncertainty, Markov models were built probabilistically, with beta 
32
In all analyses, ICERs were calculated for each alternative versus the next lowest cost.
33
Dominated comparators were excluded and the remaining alternatives compared to the 34 remaining next lowest cost, repeated as necessary. Cost-effectiveness was assessed using the M A N U S C R I P T
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8 the ICER for the most cost-effective screening strategy crossed £20,000/QALY and 1 £30,000/QALY willingness-to-pay thresholds, under otherwise base case conditions ± off-2 patent LMT costs (see Table 3 ). Scenarios in which CT yields were 2·4, 6·1 and 8·6 3 cases/index, and undiagnosed FH prevalences were 67, 33 and 24%, respectively, were also 4 considered, as theoretical analyses indicate that such undiagnosed prevalences could not be 5 reached with these CT yields. 42 Analyses were carried out using MS Excel v14.7.7.
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Results 1
The sequential cholesterol screening-genetic testing plus RCT strategy was the most cost-2 effective in all analyses, and no scenario identified an additional strategy that could be cost-3 effectively provided. The number of FH cases identified under each screening strategy, costs 4 per diagnosis, average QALYs gained, overall costs, and associated ICERs, are displayed in 5 Table 4 (DSA estimates in Supplementary Files 6 and 7). Diagnosis rates ranged from 6 11·4/10,000 screened (sequential genetic testing-cholesterol screening) to 25·4/10,000
7
(parallel cholesterol screening-genetic testing) without RCT, and 31·1/10,000 to 45·1/10,000 8 (same US strategies) with RCT. Costs per US diagnosis ranged from £11,788 (cholesterol- 
25
Threshold analysis suggested US would be cost-effective at a £20,000/QALY threshold until 26 undiagnosed prevalence reached <48% (<30% for £30,000/QALY threshold). Corresponding 27 prevalences were <43% and <28% with off-patent LMT costs. ICERs for the scenarios in 28 which undiagnosed prevalences of 67%, 33% and 24%, and respective CT yields of 2·4, 6·1 latencies to treatment and impact on the natural history of the disease will also contribute to 10 the CT versus US cost-effectiveness differences.
12
Strengths and limitations
13
This study appears to be the first to consider the cost-effectiveness of universal screening for
14
FH at 1-2 years. The study compared the multiple screening options previously noted of
15
interest, 45 and recent local data were available to estimate several parameters.
17
The persistent uncertainty around the sensitivity and specificity of different cholesterol 
26
Cholesterol thresholds of alternative sensitivity/specificity (which may impact on US 27 acceptability) could be considered in future analyses, when test performance at these 28 thresholds has been described.
30
Our analyses focused on screening at age 1-2 years, in view of recently demonstrated 31 feasibility for this age-group. Whilst this may be considered an appropriate age for screening 32 in some contexts, others have shown interest in screening school-age children.
50-53
The 33 economic implications of screening at slightly higher ages are likely to be minimal, and
34
screening at such ages could again be linked to other routine childhood healthcare M A N U S C R I P T 
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Conclusions 9
A sequential cholesterol screening-genetic testing plus RCT approach would be the most cost- 
12
Resverlogix, Abbvie, Cerenis, Cipla, Mylan, Janssen and Lilly, outside the submitted work. 
(A)
Decision tree used to estimate universal screening outcomes for each alternative. Outcomes 4 were modelled separately for the FH-positive and FH-negative individuals in each cohort, according to 5 the probabilities and formulae described in Table 1 
